{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:54Z","timestamp":1788364254012,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T00:00:00Z","timestamp":1337731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to: Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combination or sequentially following pre-existing renal damage.Describe and quantify the risk of chronic kidney disease in patients treated for ovarian cancer.<\/jats:p>\n                  <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background and Objective.<\/jats:title>\n                  <jats:p>Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long-term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Fifty-six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997\u20132010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002\u20132010. Patients were diagnosed with CKD if they had an estimated GFR &amp;lt;60 mL\/minute per 1.73 m2 for &amp;gt;3 months and were staged according to the National Kidney Foundation guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Thirteen patients (23%) developed stage \u22653 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>CKD is emerging as a potential long-term consequence of current chemotherapy for recurrent ovarian cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0422","type":"journal-article","created":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:48:26Z","timestamp":1337820506000},"page":"1534-1540","source":"Crossref","is-referenced-by-count":22,"title":["Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences?"],"prefix":"10.1093","volume":"17","author":[{"given":"Maryann","family":"Kwa","sequence":"first","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Shavit","sequence":"additional","affiliation":[{"name":"b Shaare Zedek Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Barash","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Michael","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Puzanov","sequence":"additional","affiliation":[{"name":"c Vanderbilt University Medical Center, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juri","family":"Kopolovic","sequence":"additional","affiliation":[{"name":"d Hadassah Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Rosengarten","sequence":"additional","affiliation":[{"name":"b Shaare Zedek Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Blank","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Curtin","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gabizon","sequence":"additional","affiliation":[{"name":"b Shaare Zedek Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[{"name":"a New York University Medical Center, New York, New York, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,23]]},"reference":[{"key":"2021122308235861900_B1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308235861900_B2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/djq484","article-title":"Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer","volume":"103","author":"Muggia","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122308235861900_B3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122308235861900_B4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdl484","article-title":"Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer","volume":"18","author":"Andreopoulou","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122308235861900_B5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021122308235861900_B6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"2021122308235861900_B7","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021122308235861900_B8","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"2021122308235861900_B9","volume-title":"PDR.net. Doxil (doxorubicin hcl liposome)","year":"2012"},{"key":"2021122308235861900_B10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2021122308235861900_B11","article-title":"Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results","volume":"27","author":"Muggia","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308235861900_B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","article-title":"Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer","volume":"112","author":"Muggia","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2021122308235861900_B13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"key":"2021122308235861900_B14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01612678","article-title":"Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin","volume":"116","author":"Metz-Kurschel","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122308235861900_B15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"Muggia","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 13","key":"2021122308235861900_B16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin Oncol"},{"issue":"15 suppl","key":"2021122308235861900_B17","article-title":"Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations","volume":"28","author":"Safra","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308235861900_B18","first-page":"16","article-title":"Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events","volume":"46","author":"Bertani","year":"1982","journal-title":"Lab Invest"},{"key":"2021122308235861900_B19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1046\/j.1523-1755.2000.00342.x","article-title":"Progressive Adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events","volume":"58","author":"Wang","year":"2000","journal-title":"Kidney Int"},{"key":"2021122308235861900_B20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1440-1797.2010.01383.x","article-title":"Adriamycin nephropathy: A model of focal segmental glomerulosclerosis","volume":"16","author":"Lee","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"2021122308235861900_B21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tox.2006.05.013","article-title":"Upregulation of renal eNOS by high-sodium diet facilitates hypertension in doxorubicin-treated rats through enhanced oxidative stress","volume":"225","author":"Hirai","year":"2006","journal-title":"Toxicology"},{"key":"2021122308235861900_B22","first-page":"459","article-title":"Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration","volume":"77","author":"Gabizon","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"2021122308235861900_B23","article-title":"OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC)","volume":"29","author":"Aghajanian","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122308235861900_B24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308235861900_B25","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1534\/41860239\/oncolo_17_12_1534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/12\/1534\/41860239\/oncolo_17_12_1534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T22:13:46Z","timestamp":1640297626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/12\/1534\/6403276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,23]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,5,23]]},"published-print":{"date-parts":[[2012,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0422","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,12,1]]},"published":{"date-parts":[[2012,5,23]]}}}